Investigator

August Vidal

Professor Associat Mèdic · Universitat de Barcelona, Patologia i Terapèutica Experimental

AVAugust Vidal
Papers(3)
Somatic mutation prof…Ovarian cancer relies…Absence of Nuclear p1…
Collaborators(7)
Enrique SantamaríaEsperanza Martín-Sánc…Francesc ViñalsJoaquín Fernández-Iri…José Santos-SalasJuan A. Marín‐JiménezNúria Gendrau‐Sanclem…
Institutions(5)
Departament De SalutNavarrabiomed Biomedi…Universitat de Barcel…SACYLInstitut Dinvestigaci…

Papers

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

The molecular pathogenesis of clear cell endometrial cancer (CCEC), a tumor type with a relatively unfavorable prognosis, is not well defined. We searched exome-wide for novel somatically mutated genes in CCEC and assessed the mutational spectrum of known and candidate driver genes in a large cohort of cases. We conducted whole exome sequencing of paired tumor-normal DNAs from 16 cases of CCEC (12 CCECs and the CCEC components of 4 mixed histology tumors). Twenty-two genes-of-interest were Sanger-sequenced from another 47 cases of CCEC. Microsatellite instability (MSI) and microsatellite stability (MSS) were determined by genotyping 5 mononucleotide repeats. Two tumor exomes had relatively high mutational loads and MSI. The other 14 tumor exomes were MSS and had 236 validated nonsynonymous or splice junction somatic mutations among 222 protein-encoding genes. Among the 63 cases of CCEC in this study, we identified frequent somatic mutations in TP53 (39.7%), PIK3CA (23.8%), PIK3R1 (15.9%), ARID1A (15.9%), PPP2R1A (15.9%), SPOP (14.3%), and TAF1 (9.5%), as well as MSI (11.3%). Five of 8 mutations in TAF1, a gene with no known role in CCEC, localized to the putative histone acetyltransferase domain and included 2 recurrently mutated residues. Based on patterns of MSI and mutations in 7 genes, CCEC subsets molecularly resembled serous endometrial cancer (SEC) or endometrioid endometrial cancer (EEC). Our findings demonstrate molecular similarities between CCEC and SEC and EEC and implicate TAF1 as a novel candidate CCEC driver gene. Cancer 2017;123:3261-8. © 2017 American Cancer Society.

Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix

The tumor-suppressor protein p16 is paradoxically overexpressed in cervical cancer (CC). Despite its potential as a biomarker, its clinical value and the reasons for its failure in tumor suppression remain unclear. Our purpose was to determine p16 clinical and biological significance in CC. p16 expression pattern was examined by immunohistochemistry in 78 CC cases (high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinomas of the cervix –SCCCs). CC cell proliferation and invasion were monitored by real-time cell analysis and Transwell® invasion assay, respectively. Cytoplasmic p16 interactors were identified from immunoprecipitated extracts by liquid chromatography-tandem mass spectrometry, and colocalization was confirmed by double-immunofluorescence. We observed that SCCCs showed significantly more cytoplasmic than nuclear p16 expression than HSILs. Importantly, nuclear p16 absence significantly predicted poor outcome in SCCC patients irrespective of other clinical parameters. Moreover, we demonstrated that cytoplasmic p16 interacted with CDK4 and other unreported proteins, such as BANF1, AKAP8 and AGTRAP, which could sequester p16 to avoid nuclear translocation, and then, impair its anti-tumor function. Our results suggest that the absence of nuclear p16 could be a diagnostic biomarker between HSIL and SCCC, and an independent prognostic biomarker in SCCC; and explain why p16 overexpression fails to stop CC growth.

175Works
3Papers
7Collaborators

Positions

2006–

Professor Associat Mèdic

Universitat de Barcelona · Patologia i Terapèutica Experimental

2004–

Facultativo Especialista

Hospital Universitari de Bellvitge · Anatomia Patologica

2001–

Facultativo Especialista

Institut Català d' Oncologia · Anatomia Patològica

2000–

Facultativo Especialista

Hospital Universitari de Bellvitge · Anatomia Patològica

2000–

Facultativo Especialista

Institut Català d' Oncologia · Anatomia Patològica

1996–

Facultativo Especialista

Hospital Sant Pau i Santa Tecla · Anatomia Patològica

1996–

Facultativo Especialista

Hospital Universitari de Tarragona Joan XXIII · Anatomia Patològica

1996–

Facultativo Especialista

Hospital Universitari de Bellvitge · Anatomia Patològica

Education

2005

Máster en Oncología Molecular: Bases Moleculares del Cáncer

Centro Nacional de Investigaciones Oncológicas / European School of Oncology

1995

Residencia

Hospital Universitari de Bellvitge · Anatomia Patològica

1990

Licenciado en medicina y cirugia

Universitat de Barcelona

Links & IDs
0000-0001-5727-2099

Scopus: 35433719800

Researcher Id: N-4662-2016